Development of Pyridopyrimidines as Potent Akt1/2 Inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 4, 2008, Pages 1274-1279

  Wu, Zhicai ^a   Hartnett, John C ^a   Neilson, Lou Anne ^a   Robinson, Ronald G ^a   Fu, Sheng ^a   Barnett, Stanley F ^a   Defeo Jones, Deborah ^a   Jones, Raymond E ^a   Kral, Astrid M ^a   Huber, Hans E ^a   Hartman, George D ^a   Bilodeau, Mark T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Akt; Cancer; Kinase; Pyridopyrimidine

Indexed keywords

CASPASE 3; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PYRIDOPYRIMIDINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY;

AMINES; CASPASE 3; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHIBITORY CONCENTRATION 50; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 38949215070     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.054     Document Type: Article

References (25)

1. Graff J.R. Expert Opin. Ther. Targets 6 (2002) 103
2. Nicholson K.M., and Anderson N.G. Cell. Signal. 14 (2002) 381
3. Li Q., and Zhu G.-D. Curr. Topics Med. Chem. 2 (2002) 939
4. Hanks S., and Hunter T. FASEB J. 9 (1995) 576
5. Zinda M.J., Johnson M.A., Paul J.D., Horn C., Konicek B.W., Lu Z.H., Sandusky G., Thomas J.E., Neubauer B.L., Lai M.T., and Graff J.R. Clin. Cancer Res. 7 (2001) 2475
6. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., and Testa J.R. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 3636
7. Haas-Kogan D., Shalev N., Wong M., Mills G., Yount G., and Stokoe D. Curr. Biol. 8 (1998) 1195
8. Staal S.P. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 5034
9. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Cancer Res. 61 (2001) 3986
10. Kozikowski A.P., Sun H., Brognard J., and Dennis P.A. J. Am. Chem. Soc. 125 (2003) 1144
11. Breitenlechner C.B., Wegge T., Berillon L., Graul K., Marzenell K., Friebe W., Thomas U., Huber R., Engh R.A., and Masjost B. J. Med. Chem. 47 (2004) 1375
12. Hsu J.H., Shi Y., Hu L.P., Fisher M., Franke T.F., and Lichtenstein A. Oncogene 21 (2002) 1391
13. Page C., Lin H., Jin Y., Castle V.P., Nunez G., Huang M., and Lin J. Anticancer Res. 20 (2000) 407
14. Barnett S., Bilodeau M., and Lindsley C. Curr. Top. Med. Chem. 5 (2005) 109
15. Li Q., and Zhu G.-D. Curr. Top. Med. Chem. 2 (2002) 939
16. Zhu G.-D., Gandhi V.B., Gong J., Thomas S., Woods K.W., Song X., Li T., Diebold R.B., Luo Y., Liu X., Guan R., Klinghofer V., Johnson E.F., Bouska J., Olson A., Marsh K.C., Stoll V.S., Mamo M., Polakowski J., Campbell T.J., Martin R.L., Gintant G.A., Penning T.D., Li Q., Rosenberg S.H., and Giranda V.L. J. Med. Chem. 50 (2007) 2990
17. Defeo-Jones D., Barnett S.F., Fu S., Hancock P.J., Haskell K.M., Leander K.R., McAvoy E., Robinson R.G., Duggan M.E., Lindsley C.W., Zhao Z., Huber H.E., and Jones R.E. Mol. Cancer Ther. 4 (2005) 271
18. Lindsley C.W., Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., and Duggan M.E. Bioorg. Med. Chem. Lett. 15 (2005) 761
19. Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., Duggan M.E., and Lindsley C.W. Bioorg. Med. Chem. Lett. 15 (2005) 905
20. Barnett S.F., Defeo-Jones D., Fu S., Hancock P.J., Haskell K.M., Jones R.E., Kahana J.A., Kral A., Leander K., Lee L.L., Malinowski J., McAvoy E.M., Nahas D.D., Robinson R., and Huber H.E. Biochem. J. 385 (2005) 399
21. Wu, Z.; Robinson, R. G.; Fu, S.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Kral, A. M.; Huber, H. E.; Kohl, N. E.; Hartman, G. D.; Bilodeau, M. T. Bioorg. Med. Chem. Lett., in press.
22. Zhao Z., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huber H.E., Duggan M.E., and Lindsley C.W. Bioorg. Med. Chem. Lett. 18 (2008) 49
23. 50 represents biochemical inhibition of peptide phosphorylation. Detection was performed by homogeneous time resolved fluorescence (HTRF) using an europium chelate (Perkin-Elmer) [Eu(K)]-labeled phospho(S21)-GSK3α antibody (Cell Signaling Technologies) and streptavidin-linked XL665 fluorophore which binds to the biotin moiety on the substrate peptide (biotin-GGRARTSSFAEPG). For detail see Ref. 5. Values are reported as single determinations or as the average of at least two determinations ±standard deviation.
24. 50 values represent the ability of inhibitors to block the phosphorylation of Akt isozymes in C33 A cells (human cervical carcinoma). For detail see Ref. 6. Values are reported as single determinations or as the average of at least two determinations ±standard deviation.
25. Choi-Sledeski Y.M., Kearney R., Poli G., Pauls H., Gardner C., Gong Y., Becker M., Davis R., Spada A., Liang G., Chu V., Brown K., Collussi D., Leadley R., Rebello S., Moxey P., Morgan S., Bentley R., Kasiewski C., Maignan S., Guilloreau J.P., and Mikol V. J. Med. Chem. 46 (2003) 681